Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon β 1a) in Patients With Relapsing-Remitting Multiple Sclerosis
Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon β 1a) in Patients With Relapsing-Remitting Multiple Sclerosis
The primary study objective is to test the superiority of Daclizumab High Yield Process (DAC HYP) compared to interferon β 1a (IFN β-1a) in preventing multiple sclerosis (MS) relapse in participants with relapsing remitting multiple sclerosis.
The secondary study objectives are to test the superiority of DAC HYP compared to IFN β-1a in slowing functional decline and disability progression and maintaining quality of life in this participant population.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.
Worchester, Massachusetts, United States
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Brno, South Bohemian Region, Czechia
Hyderabad, Andhra Pradesh, India
Tzfat, Israel
Lublin, Lower Silesian Voivodeship, Poland
Bydgoszczas, Poland
Lódz, Łódź Voivodeship, Poland
Bucurest, Bucharest, Romania
Târgu Mures, Romania
Kyviv, Ukraine
New Castle Upon Tyne, United Kingdom